| Authors: |
Amano Y; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Takeda Pharmaceutical Co., Ltd., Hara H; Takeda Pharmaceutical Co., Ltd., Takakura I; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Kissei Pharmaceutical Co., Ltd., Tanaharu T; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Bristol-Myers Squibb K.K., Motoyama K; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Johnson & Johnson Innovative Medicine., Nishikawa S; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Tanabe Pharma Corporation., Kurooka T; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; EA Pharma Co., Ltd., Sakai K; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; ASKA Pharmaceutical Co., Ltd., Sato G; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Eisai Co., Ltd., Hashimoto K; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Takeda Pharmaceutical Co., Ltd., Suzuki M; Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA).; Kyowa Kirin Co., Ltd. |
